Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Avalo Therapeutics Inc (AVTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: AVTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -94.18% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 48.40M USD | Price to earnings Ratio 0.04 | 1Y Target Price 29.88 |
Price to earnings Ratio 0.04 | 1Y Target Price 29.88 | ||
Volume (30-day avg) 85555 | Beta 0.71 | 52 Weeks Range 3.39 - 16.00 | Updated Date 06/18/2025 |
52 Weeks Range 3.39 - 16.00 | Updated Date 06/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 118.98 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 16556.01% | Operating Margin (TTM) -11408.39% |
Management Effectiveness
Return on Assets (TTM) -23.98% | Return on Equity (TTM) 67.82% |
Valuation
Trailing PE 0.04 | Forward PE - | Enterprise Value -75845539 | Price to Sales(TTM) 109.75 |
Enterprise Value -75845539 | Price to Sales(TTM) 109.75 | ||
Enterprise Value to Revenue 2.74 | Enterprise Value to EBITDA -0.19 | Shares Outstanding 10827600 | Shares Floating 3682149 |
Shares Outstanding 10827600 | Shares Floating 3682149 | ||
Percent Insiders 6.39 | Percent Institutions 76.24 |
Analyst Ratings
Rating 4.62 | Target Price 32 | Buy 1 | Strong Buy 6 |
Buy 1 | Strong Buy 6 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Avalo Therapeutics Inc
Company Overview
History and Background
Avalo Therapeutics, Inc. (AVTX), formerly Cerecor Inc. and Aevi Genomic Medicine, has undergone significant transformations. Founded to address rare diseases and cancer, the company has focused on precision medicine and targeted therapies through various acquisitions and strategic shifts.
Core Business Areas
- AVTX: Avalo Therapeutics focuses on developing and commercializing targeted therapies for unmet medical needs in immunology, hematology, and oncology.
Leadership and Structure
The leadership team consists of individuals with experience in biotechnology and pharmaceuticals. The organizational structure is typical of a clinical-stage biopharmaceutical company.
Top Products and Market Share
Key Offerings
- AVTX-801 (d-serine): Previously in development for inborn errors of metabolism, particularly cerebral creatine deficiency syndromes (CCDS). D-serine aimed to improve NMDA receptor function. Development has been discontinued. No significant market share data or revenue available. Competitors included companies working on similar rare genetic disorders.
- Anti-LIGHT mAb: Avalo is focused on its anti-LIGHT mAb program. LIGHT is a target implicated in immune-mediated inflammatory diseases (IMIDs). The drug is in preclinical development for inflammatory indications. Market share and revenue data is not available. Competitors would be companies developing treatments for IMIDs.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and competition. Companies focus on developing and marketing new drugs, often relying on patents for market exclusivity.
Positioning
Avalo Therapeutics is positioning itself in the immunology, hematology, and oncology space. Competitive advantages would be based on the novelty and effectiveness of its therapeutics.
Total Addressable Market (TAM)
The TAM for targeted therapies in immunology, hematology, and oncology is substantial, potentially exceeding hundreds of billions of dollars. Avalo's positioning depends on the success of its clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Targeted therapeutic approach
- Experienced leadership team
- Pipeline of therapeutic candidates
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- History of strategic changes
Opportunities
- Partnerships and collaborations
- Successful clinical trial results
- Regulatory approvals
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory delays
- Funding constraints
Competitors and Market Share
Key Competitors
- JAZZ
- ARGX
- BMY
Competitive Landscape
Avalo faces significant competition from established pharmaceutical companies with greater resources. Success depends on demonstrating superior efficacy and safety.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historically, growth has been tied to acquisitions, licensing agreements, and clinical development milestones.
Future Projections: Future growth hinges on the success of its anti-LIGHT mAb program and other pipeline assets.
Recent Initiatives: The company is focused on advancing its anti-LIGHT mAb through preclinical and clinical development.
Summary
Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapies. The company faces considerable risks, including reliance on clinical trial results and limited financial resources. Its success will depend on the advancement of its key drug candidates and strategic partnerships. They need to prove that their approach is solid in a difficult market to thrive. Their future success hinges on demonstrating clinical benefits and securing funding.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Third-party financial data providers
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avalo Therapeutics Inc
Exchange NASDAQ | Headquaters Rockville, MD, United States | ||
IPO Launch date 2015-11-13 | President, CEO & Director Dr. Garry A. Neil M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | Website https://www.avalotx.com |
Full time employees 23 | Website https://www.avalotx.com | ||
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.